Literature DB >> 2720567

Prognostic significance of epidermal growth factor receptor in esophageal squamous cell carcinomas.

S Ozawa1, M Ueda, N Ando, N Shimizu, O Abe.   

Abstract

The prognostic value of epidermal growth factor (EGF) receptor level was studied in 32 patients with esophageal squamous cell carcinoma. The EGF receptor levels of tumors were measured by iodine 125 (125I)-EGF binding assay, and the patients subsequently were divided into two groups: a group with high EGF binding capacities (greater than or equal to 2.5% of input), and a group with low EGF binding capacities (less than 2.5% of input). The cumulative survival rates for the two groups were calculated by the Kaplan-Meier method. The generalized Wilcoxon test indicated that the survival rate of the high EGF binding group was significantly lower than that of the low EGF binding group (P less than 0.05). In tumors from two patients with the highest EGF receptor levels, EGF receptor gene amplification was observed. These patients developed mediastinal lymph node metastasis and died 4 and 11 months after surgery, respectively. These results suggest that elevated EGF receptor level is a significant prognostic indicator for esophageal squamous cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2720567     DOI: 10.1002/1097-0142(19890601)63:11<2169::aid-cncr2820631117>3.0.co;2-w

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  39 in total

1.  Matrix-independent survival of human keratinocytes through an EGF receptor/MAPK-kinase-dependent pathway.

Authors:  M Jost; T M Huggett; C Kari; U Rodeck
Journal:  Mol Biol Cell       Date:  2001-05       Impact factor: 4.138

2.  Chemoradiotherapy for esophageal cancer.

Authors:  Geoffrey Neuner; Ashish Patel; Mohan Suntharalingam
Journal:  Gastrointest Cancer Res       Date:  2009-03

3.  Genetic alterations in patients with esophageal cancer with short- and long-term survival rates after curative esophagectomy.

Authors:  Y Shimada; M Imamura; I Shibagaki; H Tanaka; T Miyahara; M Kato; K Ishizaki
Journal:  Ann Surg       Date:  1997-08       Impact factor: 12.969

Review 4.  Biologic markers, cellular differentiation, and metastatic head and neck cancer.

Authors:  S P Schantz
Journal:  Eur Arch Otorhinolaryngol       Date:  1993       Impact factor: 2.503

5.  PCNA immunostaining combined with AgNOR staining in esophageal squamous cell carcinoma to identify patients with a poor prognosis.

Authors:  Y Morisaki; S Shima; Y Yoshizumi; Y Sugiura; S Tanaka; S Tamai
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

6.  Expression of growth factors and their receptors in human esophageal carcinomas: regulation of expression by epidermal growth factor and transforming growth factor alpha.

Authors:  K Yoshida; H Kuniyasu; W Yasui; Y Kitadai; T Toge; E Tahara
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

7.  Role of GPER1, EGFR and CXCR1 in differentiating between malignant follicular thyroid carcinoma and benign follicular thyroid adenoma.

Authors:  Le Zhao; Xiao-Yun Zhu; Rong Jiang; Man Xu; Ni Wang; George G Chen; Zhi-Min Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 8.  Role of epidermal growth factor receptor in breast cancer.

Authors:  Hiroko Masuda; Dongwei Zhang; Chandra Bartholomeusz; Hiroyoshi Doihara; Gabriel N Hortobagyi; Naoto T Ueno
Journal:  Breast Cancer Res Treat       Date:  2012-10-17       Impact factor: 4.872

9.  Prognostic significance of epidermal growth factor receptor in squamous cell carcinoma of the maxillary sinus.

Authors:  M Miyaguchi; S Sakai; J Olofsson; H Kuwabara; H Sakamoto
Journal:  Eur Arch Otorhinolaryngol       Date:  1993       Impact factor: 2.503

10.  High expression of GPER1, EGFR and CXCR1 is associated with lymph node metastasis in papillary thyroid carcinoma.

Authors:  Cui Tang; Lei Yang; Ni Wang; Li Li; Man Xu; George G Chen; Zhi-Min Liu
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.